Question explored with the scientific record
Conversation so far
- 1 Why is Ajovy available only in 225mg syringes? Why is there no 175mg, for example? How did the drug manufacturer arrive at that dose and can I see that data? What dose ranges did they test?
- 2 What does it imply if an adult can take Ajovy 225mg every two months instead of monthly? does it imply the 225mg dose is an overshoot for this particular person? if the half-life is 30 days and the drug works great for 60 days, what do we learn from that?
- 3 Do any guidelines address stretching Ajovy dosing beyond 30 days?
- 4 Are there any studies on dosing at 45 or 60 days for Ajovy?
Answered on this page ↓
Are there any studies on dosing at 45 or 60 days for Ajovy?
The short version: no study in the retrieved evidence tests a 45-day or 60-day dosing interval for Ajovy.
The phase 3 trials tested only monthly (225 mg) and quarterly (675 mg) regimens [1]. A 2025 real-world study of 165 patients compared those same two schedules and found no significant difference in migraine-day reduction between them over 24 months [2]. The drug's half-life of about 30 days means a 60-day interval would leave blood levels lower than monthly dosing but higher than quarterly dosing in the second month [3]. That is a plausible middle ground, but no retrieved record tests it directly.
The evidence base for this exact question is empty. No dose-finding study for intermediate intervals appears in this retrieval. No guideline addresses 45-day or 60-day stretching. The manufacturer funded the pivotal trials [1]. The real-world study is a single-center retrospective cohort, not a randomized trial [2].
My call: stretching to 45 or 60 days is plausible given that quarterly dosing works, but no study supports it directly. Confidence: low.
Sources used 3
-
Fremanezumab for prophylaxis of migraine in adults
Fremanezumab, an anti-CGRP monoclonal antibody, significantly reduced monthly migraine and headache days versus placebo in phase 3 trials of episodic and chronic migraine and was well tolerated.
DOI: 10.1002/psb.1818 -
A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
In a single-center retrospective cohort of 165 migraine patients, fremanezumab significantly reduced monthly migraine days through 24 months, with comparable efficacy for monthly and quarterly dosing and greater treatment persistence with quarterly dosing.
DOI: 10.1186/s42466-025-00395-y -
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Single fremanezumab doses (225, 675, 900 mg) showed similar pharmacokinetics and safety in healthy Japanese and Caucasian subjects, with no anti-drug antibodies.
DOI: 10.1177/0333102418771376